335 related articles for article (PubMed ID: 33951889)
1. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
[TBL] [Abstract][Full Text] [Related]
2. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
[TBL] [Abstract][Full Text] [Related]
3. Exploration and analysis of differentially expressed genes in Epstein-Barr virus negative and positive plasmablastic lymphoma.
Liang Y; Wang H; Luo B
Clin Transl Oncol; 2023 Oct; 25(10):2884-2891. PubMed ID: 36991219
[TBL] [Abstract][Full Text] [Related]
4. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.
Leeman-Neill RJ; Soderquist CR; Montanari F; Raciti P; Park D; Radeski D; Mansukhani MM; Murty VV; Hsiao S; Alobeid B; Bhagat G
Haematologica; 2022 Jan; 107(1):201-210. PubMed ID: 33297669
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and genetic landscape of plasmablastic lymphoma in Taiwan.
Chen BJ; Hsieh TH; Yuan CT; Wang RC; Yang CF; Chuang WY; Su YZ; Ho CH; Lin CH; Chuang SS
Pathol Res Pract; 2024 Jan; 253():155059. PubMed ID: 38160484
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.
Mansoor A; Akhter A; Kamran H; Minoo P; Stewart D
Hum Pathol; 2023 Nov; 141():102-109. PubMed ID: 37524252
[TBL] [Abstract][Full Text] [Related]
7. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.
Meer S; Perner Y; McAlpine ED; Willem P
Histopathology; 2020 Jan; 76(2):212-221. PubMed ID: 31361906
[TBL] [Abstract][Full Text] [Related]
8. Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma.
Liu F; Tian S; Liu Q; Deng Y; He Q; Shi Q; Chen G; Xu X; Yuan J; Nakamura S; Karube K; Wang Z
Cancer Med; 2024 Feb; 13(4):e6995. PubMed ID: 38457199
[TBL] [Abstract][Full Text] [Related]
9. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.
Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Loghavi S; Gomez Mediavilla A; Tonda R; Beltran S; Gut M; Pereña Gonzalez A; d'Ámore E; Visco C; Khoury JD; Montes-Moreno S
Haematologica; 2021 Apr; 106(4):1120-1128. PubMed ID: 32273478
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.
Liu Z; Filip I; Gomez K; Engelbrecht D; Meer S; Lalloo PN; Patel P; Perner Y; Zhao J; Wang J; Pasqualucci L; Rabadan R; Willem P
Blood Cancer Discov; 2020 Jul; 1(1):112-125. PubMed ID: 33225311
[TBL] [Abstract][Full Text] [Related]
11. From the archives of MD Anderson Cancer Center: Plasmablastic lymphoma presenting as a kidney mass in an immunocompetent patient: Case report and literature review.
Gietzen R; Muthukumarana V; Bhargava P; Vozniuk D; Thakral B; Medeiros LJ; Lyapichev KA
Ann Diagn Pathol; 2023 Dec; 67():152186. PubMed ID: 37541853
[TBL] [Abstract][Full Text] [Related]
12. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
Laurent C; Fabiani B; Do C; Tchernonog E; Cartron G; Gravelle P; Amara N; Malot S; Palisoc MM; Copie-Bergman C; Glehen AT; Copin MC; Brousset P; Pittaluga S; Jaffe ES; Coppo P
Haematologica; 2016 Aug; 101(8):976-84. PubMed ID: 27175027
[TBL] [Abstract][Full Text] [Related]
13. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.
Taddesse-Heath L; Meloni-Ehrig A; Scheerle J; Kelly JC; Jaffe ES
Mod Pathol; 2010 Jul; 23(7):991-9. PubMed ID: 20348882
[TBL] [Abstract][Full Text] [Related]
14. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.
Valera A; Balagué O; Colomo L; Martínez A; Delabie J; Taddesse-Heath L; Jaffe ES; Campo E
Am J Surg Pathol; 2010 Nov; 34(11):1686-94. PubMed ID: 20962620
[TBL] [Abstract][Full Text] [Related]
15. Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.
Gebauer N; Künstner A; Ketzer J; Witte HM; Rausch T; Benes V; Zimmermann J; Gebauer J; Merz H; Bernard V; Harder L; Ratjen K; Gesk S; Peter W; Busch Y; Trojok P; von Bubnoff N; Biersack H; Busch H; Feller AC
Blood Cancer J; 2021 May; 11(5):102. PubMed ID: 34039950
[TBL] [Abstract][Full Text] [Related]
16. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farré B; Balagué O; Celis V; Nadeu F; Salmerón-Villalobos J; Andrés M; Martin-Guerrero I; Garrido-Pontnou M; Gaafar A; Suñol M; Bárcena C; Garcia-Bragado F; Andión M; Azorín D; Astigarraga I; Sagaseta de Ilurdoz M; Sábado C; Gallego S; Verdú-Amorós J; Fernandez-Delgado R; Perez V; Tapia G; Mozos A; Torrent M; Solano-Páez P; Rivas-Delgado A; Dlouhy I; Clot G; Enjuanes A; López-Guillermo A; Galera P; Oberley MJ; Maguire A; Ramsower C; Rimsza LM; Quintanilla-Martinez L; Jaffe ES; Campo E; Salaverria I
Blood; 2020 Jan; 135(4):274-286. PubMed ID: 31738823
[TBL] [Abstract][Full Text] [Related]
17. Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways.
Mansoor A; Kamran H; Akhter A; Seno R; Torlakovic EE; Roshan TM; Shabani-Rad MT; Elyamany G; Minoo P; Stewart D
Mod Pathol; 2023 Aug; 36(8):100198. PubMed ID: 37105495
[TBL] [Abstract][Full Text] [Related]
18. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.
Frontzek F; Staiger AM; Zapukhlyak M; Xu W; Bonzheim I; Borgmann V; Sander P; Baptista MJ; Heming JN; Berning P; Wullenkord R; Erdmann T; Lutz M; Veratti P; Ehrenfeld S; Wienand K; Horn H; Goodlad JR; Wilson MR; Anagnostopoulos I; Lamping M; Gonzalez-Barca E; Climent F; Salar A; Castellvi J; Abrisqueta P; Menarguez J; Aldamiz T; Richter J; Klapper W; Tzankov A; Dirnhofer S; Rosenwald A; Mate JL; Tapia G; Lenz P; Miething C; Hartmann W; Chapuy B; Fend F; Ott G; Navarro JT; Grau M; Lenz G
Nat Commun; 2021 Aug; 12(1):5183. PubMed ID: 34465776
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma.
Zhou T; Cheng J; Karrs J; Davies-Hill T; Pack SD; Xi L; Tyagi M; Kim J; Jaffe ES; Raffeld M; Pittaluga S
Am J Surg Pathol; 2022 Oct; 46(10):1364-1379. PubMed ID: 35650679
[TBL] [Abstract][Full Text] [Related]
20. Plasmablastic Lymphoma of the Small Intestine in an HIV- and EBV-negative Patient.
Fukuo Y; Shibuya T; Ashizawa K; Ito K; Saeki M; Fukushima H; Takahashi M; Nomura K; Okahara K; Haga K; Akazawa Y; Nomura O; Ogura K; Okubo H; Nagahara A
Intern Med; 2021 Sep; 60(18):2947-2952. PubMed ID: 33776007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
